ArticleCurrent oncology (Toronto, Ont.)2020
Consensus recommendations for optimizing biomarker testing to identify and treat advanced
Article in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.PloS one · 2025Pooled it
- Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives.Frontiers in genetics · 2023Pooled it
- Biomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms-A Brief Report.JTO clinical and research reports · 2026Article
- Synonymous Variants of Potential Significance Identified by a 52-Gene Clinical Sequencing Panel in Non-Small Cell Lung Cancer.Genes, chromosomes & cancer · 2026Article
- Strategies for improving biomarker testing rates in non-small cell lung cancer in north America: a scoping review.Journal of thoracic disease · 2025Review
- Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer Management.JTO clinical and research reports · 2025Article
- Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations.The oncologist · 2025Review
- Article
- Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study.Lancet regional health. Americas · 2024Article
- Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective.Current oncology (Toronto, Ont.) · 2024Article
- Non-Coding RNA as a Biomarker in Lung Cancer.Non-coding RNA · 2024Review
- Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre.Current oncology (Toronto, Ont.) · 2024Article
- Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: Experience at a tertiary academic institution in Canada.Cancer medicine · 2024Article
- Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.Current oncology (Toronto, Ont.) · 2023Article
- Review
- Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.Cancer medicine · 2023Article
- FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC.Pathology oncology research : POR · 2023Article
- Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness?Healthcare (Basel, Switzerland) · 2022Article
- Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2022Review
- Canadian Consensus Recommendations on the Management ofCurrent oncology (Toronto, Ont.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for patients with nsclc now involves testing for multiple biomarkers, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.